Objective: To investigate the prevalence of abnormal cervical cytological findings and local risk factors in Ibadan, Nigeria. Study Design: All women aged ≥15 years in each household in Idikan, Ibadan, were invited to participate in a population-based study. Structured questionnaires were administered to all consenting women. Conventional cervical Papanicolaou smears obtained from sexually active women were classified using the 2001 Bethesda system. The diagnoses were correlated with sociodemographic data and risk factors. Results: Of 2,870 women aged ≥15 years estimated to live in Idikan, 1,204 sexually active women consented to pelvic examination and cervical smears. Results were available for 1,104 women (mean age: 39.8 years). Mean ages at menarche, first sexual intercourse and first pregnancy were 16.1, 20.3 and 20.7 years, respectively. Cytological results were categorized into atypical squamous cells of undetermined significance and atypical glandular cells 22 (1.99%); low-grade 43 (3.89%) and high-grade squamous intraepithelial lesions (HSIL) 17 (1.54%); invasive cancer 2 (0.18%) and normal 593 (53.8%) and reactive changes 427 (38.7%). The prevalence of epithelial abnormalities is 7.6%. Significant host-related factors in those with HSIL and invasive cancer included older age (mean 56.2 years), high parity and gravidity, lack of formal education and being divorced (p < 0.05). Conclusions: This study provides prevalence data and local risk factors for abnormal cervical cytology in a Nigerian population, which will be useful for planning future cervical cancer control programs.

Keywords:
Abnormal cervical cytology, Cervical cancer control, Cervical screening, Ibadan, Nigeria, Prevalence
1.
Parkin DM, Bray F: The burden of human papillomavirus-related cancers. Vaccine 2006;24(suppl 3):11–25.
2.
Thomas JO: Cancer in Nigeria; in Parkin DM, Ferlay J, Hamdi-Cherif M, Sitas F, Thomas JO, Wabinga H, Whelan SL (eds): Cancer in Africa. Epidemiology and Prevention. IARC Scientific Publications No. 153. Lyon, IARCPress, 2003.
3.
Herrero R: Epidemiology of cervical cancer. J Natl Cancer Inst Monogr 1996;21:1–6.
4.
Eddy DM: Screening for cervical cancer. Ann Intern Med 1990;113:214–226.
5.
Anorlu RI: Cervical cancer. The sub-Saharan African perspective. Reprod Health Matters 2008;32:41–49.
6.
Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, et al: Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008;37:536–546.
7.
Girianelli VR, Azevedo E, Silva G, Thuler LC: Factors associated with the risk of progression to precursor lesions or cervical cancer in women with negative cytologic findings. Int J Gynaecol Obstet 2009;107:228–231.
8.
Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al: Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002;329:1093–1101.
9.
Bayo S, Bosch FX, de Sanjose S, Munoz N, Combita AL, Coursaget P, et al: Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 2002;31:202–209.
10.
Varghese C, Amma NS, Chitrathara K, Dhakad N, Rai P, Malathy L, Nair MK: Risk factors for cervical dysplasia in Kerala India. Bull World Health Organ 1999;77:281–283.
11.
Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, et al: Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:2148–2153.
12.
Appleby P, Beral V, Berrington DE, González A, Colin D, Franceschi S, et al: Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118:1481–1495.
13.
Franceschi S, Plummer M, Clifford G, de Sanjose S, Bosch X, Herrero R, et al: Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer 2009;101:865–870.
14.
de Gois Speck NM, Pereira ER, Schaper M, Rodrigues D, Almeida P, Sakano CR, Ribalta JC: Cytopathological screening in indigenous women from Parque Indigena do Xingu. Eur J Gynaecol Oncol 2009;30:512–513.
15.
Thomas JO, Herrero R, Ojemakinde K, Omigbodun AA, Ajayi IO, Fawole A, Oladepo A: Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004;90:638–645.
16.
Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009;199:919–922.
17.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009;374:268–270.
18.
Bonanni P, Boccalini S, Bechini A: Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009;27(suppl 1):A46–A53.
19.
Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C: Screening, prevention and treatment of cervical cancer – global and regional generalized cost-effectiveness analysis. Vaccine 2009;27:6060–6079.
20.
Franco EL, Coutlee F, Ferenczy A: Integrating human papillomavirus vaccination in cervical cancer control programmes. Public Health Genomics 2009;12:352–361.
21.
Shannon J, Thomas DB, Ray RM, Kestin M, Koetsawang A, Koetsawang C, et al: Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. Cancer Causes Control 2002;13:691–699.
22.
Shikany JM, Heimurger DC, Piyathilake CJ, Desmond RA, Greene PG: Effect of folic acid fortification of foods on folate intake in female smokers with cervical dysplasia. Nutrition 2004;20:409–414.
23.
Hernandez BY, McDuffie K, Wilkens LR, Kamemoto L, Goodman MT: Diet and premalignant lesions of the cervix: evidence of a protective role for folate, riboflavin, thiamine, and vitamin B12. Cancer Causes Control 2003;14:859–870.
24.
Cho H, Kim MK, Lee JK, Son SK, Lee KB, Lee JM, Lee JP, Hur SY, Kim JH: Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study. Clin Chem Lab Med 2009;47:1005–1012.
25.
Zhang ZF, Parkin DM, Yu SZ, Esteve J, Yang XZ: Risk factors for cancer of the cervix in a rural Chinese population. Int J Cancer 1989;43:762–767.
26.
Thomas JO, Babarinsa IA, Ajayi IO, Fawole O, Ojemakinde KO, Omigbodun AO, Oladepo AO: Mobilization for cervical screening: lessons from a poor-urban Yoruba community in Nigeria. Afr J Med Med Sci 2005;34:81–85.
27.
Dim CC, Ekwe E, Madubuko T, Dim NR, Ezegwui HU: Improved awareness of Pap smear may not affect its use in Nigeria: a case study of female medical practitioners in Enugu, southeastern Nigeria. Trans R Soc Trop Med Hyg 2009;103:852–854.
28.
Aniebue PN, Aniebue UU: Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. J Cancer Educ 2010 2010;25:106–108.
29.
Adefuye PO: Knowledge and practice of cervical screening among professional health workers in a suburban district in Nigeria. Nig Med Pract 2006;50:19–22.
30.
Sawaya GF, McConnell KJ, Kulasingam SL, Lawson HW, Kerlikowske K, Melnikow J, et al: Risk of cervical cancer associated with extending the interval between cervical cancer screenings. N Engl J Med 2003;349:1501–1509.
31.
Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Melnikow J, et al: Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal Pap tests. Obstet Gynecol 2006;107:321–328.
32.
Clinical Management of Guidelines for Obstetrician-Gynecologists. ACOG Practice Bulletin 109. Washington, American College of Obstetricians & Gynecologists, 2009, pp 1–9.
33.
Sasieni P, Adams J, Cuzick J: Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88–93.
34.
Dim CC, Nwagha UI, Ezegwui HU, Dim NR: The need to incorporate routine cervical cancer counselling and screening in the management of women at the outpatient clinics in Nigeria. J Obstet Gynaecol 2009;29:754–756.
35.
Peters LM, Soliman AS, Bukori P, Mkuchu J, Ngoma T: Evidence for the need of educational programs for cervical screening in rural Tanzania. J Cancer Educ 2010;25:153–159.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.